Please login to the form below

Not currently logged in
Email:
Password:

Array Biopharma hires Dr Howard Holden as VP regulatory affairs

Will oversee attempts to bring to market pipeline of small molecule drugs to treat cancer and inflammatory diseases

Dr Howard Holden has joined Array Biopharma as VP of regulatory affairs and quality assurance.

Dr Holden will handle regulatory proceedings as the US biopharma aims to bring to market its pipeline of small molecule drugs to treat cancer and inflammatory diseases.

He has spent over 25 years in the pharma and biotech industry, including most recently 7 years at Nereus Pharmaceuticals as senior VP regulatory affairs and compliance.

Previously, Dr Holden was VP of regulatory affairs and compliance at Stressgen Biotechnologies and Ligand Pharmaceuticals; senior director at Parke-Davis/Warner-Lambert, director at Centocor and senior investigator at the US National Cancer Institute.

"Howard's lifetime of regulatory experience will help Array navigate the FDA approval path for our proprietary programmes," said Kyle Lefkoff, executive chair, Array BioPharma.

"He will make an immediate contribution as we move our pipeline into registration studies, and we're all excited to have Howard on the Array team."

27th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics